These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2791187)

  • 21. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes.
    Unezaki S; Maruyama K; Ishida O; Takahashi N; Iwatsuru M
    J Drug Target; 1993; 1(4):287-92. PubMed ID: 8069570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II).
    Harashima H; Midori Y; Ohshima S; Yachi K; Kikuchi H; Kiwada H
    Biopharm Drug Dispos; 1993 Oct; 14(7):595-608. PubMed ID: 8251614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.
    Gabizon A; Shiota R; Papahadjopoulos D
    J Natl Cancer Inst; 1989 Oct; 81(19):1484-8. PubMed ID: 2778836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
    Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposome-mediated therapy of intracranial brain tumors in a rat model.
    Sharma US; Sharma A; Chau RI; Straubinger RM
    Pharm Res; 1997 Aug; 14(8):992-8. PubMed ID: 9279878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia.
    Maruyama K; Unezaki S; Takahashi N; Iwatsuru M
    Biochim Biophys Acta; 1993 Jul; 1149(2):209-16. PubMed ID: 8323940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models.
    Gabizon A; Goren D; Barenholz Y
    Isr J Med Sci; 1988; 24(9-10):512-7. PubMed ID: 3204005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.
    El-Kareh AW; Secomb TW
    Neoplasia; 2000; 2(4):325-38. PubMed ID: 11005567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
    Peer D; Margalit R
    Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.
    Forssen EA; Tökès ZA
    Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1873-7. PubMed ID: 6940195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes.
    Storm G; Steerenberg PA; Emmen F; van Borssum Waalkes M; Crommelin DJ
    Biochim Biophys Acta; 1988 May; 965(2-3):136-45. PubMed ID: 3365449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposome drug delivery system for murine neuroblastoma.
    Nagae I; Koyanagi Y; Ito S; Tanabe Y; Unezaki S
    J Pediatr Surg; 1998 Oct; 33(10):1521-5. PubMed ID: 9802805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardioprotective roles of aged garlic extract, grape seed proanthocyanidin, and hazelnut on doxorubicin-induced cardiotoxicity.
    Demirkaya E; Avci A; Kesik V; Karslioglu Y; Oztas E; Kismet E; Gokcay E; Durak I; Koseoglu V
    Can J Physiol Pharmacol; 2009 Aug; 87(8):633-40. PubMed ID: 19767888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.
    Mayer LD; Bally MB; Cullis PR; Wilson SL; Emerman JT
    Cancer Lett; 1990 Sep; 53(2-3):183-90. PubMed ID: 2208078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
    Cusack BJ; Young SP; Driskell J; Olson RD
    Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization and upscaling of doxorubicin-containing liposomes for clinical use.
    Amselem S; Gabizon A; Barenholz Y
    J Pharm Sci; 1990 Dec; 79(12):1045-52. PubMed ID: 2079648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicin.
    Ishisaka T; Kishi S; Okura K; Horikoshi M; Yamashita T; Mitsuke Y; Shimizu H; Ueda T
    Leuk Lymphoma; 2006 Aug; 47(8):1599-607. PubMed ID: 16966272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
    Herman EH; Rahman A; Ferrans VJ; Vick JA; Schein PS
    Cancer Res; 1983 Nov; 43(11):5427-32. PubMed ID: 6616474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
    Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
    BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.